chevron_leftBack
As of 24 April 2025, Vetoquinol S.A. has a market cap of $1.03B USD, ranking #8039 globally and #138 in France. It ranks #780 in the Healthcare sector, and #177 in the Drug Manufacturers - Specialty & Generic industry.
Key Stats
Market Cap
$1.03BUSD
908.74M EUR
Enterprise Value
$869.08MUSD
766.89M EUR
Revenue (TTM)
$613.58MUSD
539.2M EUR
EBITDA (TTM)
$119.9MUSD
105.8M EUR
Net Income (TTM)
$66.8MUSD
58.7M EUR
EBITDA Margin
20%
Profit Margin
11%
PE Ratio
15.5
Company Profile
Country (HQ)
Sector
Healthcare
CEO
Matthieu Frechin
open_in_new
Employees
2,440
Founded
1933
Website
vetoquinol.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| 1.8% | -0.8% | -11% | 19% | -7.6% | -23% |
Upcoming Earnings
Earnings Date
Thu, Apr 24
Today
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
VETO
Vetoquinol SA
ISIN: FR0004186856
Shares Out.:
Shares Outstanding:
11.832M1
Shares Float:
3.859M2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
BA:
Barron's:
MS:
Morningstar:
|
78.20 EUR | |
|
0O1O
Vetoquinol SA
ISIN: FR0004186856
Shares Out.:
Shares Outstanding:
11.832M1
Shares Float:
3.859M2
|
77.40 EUR |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About Vetoquinol S.A.
Vetoquinol SA, a veterinary pharmaceutical company, designs, develops, and sells veterinary drugs and non-medicinal products in Europe, the Americas, and the Asia Pacific region. It provides products in the areas of mobility, pain, and inflammation; dermatology, hygiene, and care; anti-parasite; udder health; infectious diseases; reproduction; behavior management; internal medicine; and cardiology-nephrology for cattle, sheep, pigs, poultry, dogs, cats, and horses. The company was founded in 1933 and is headquartered in Lure, France. Vetoquinol SA is a subsidiary of Soparfin SCA.
